INKT (MiNK Therapeutics) Total Debt per Share: $0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INKT MiNK Therapeutics Inc INKT
31 GF Score
Price $11.32
! 1 Warning Sign
View Full Analysis

What is MiNK Therapeutics Total Debt per Share?

MiNK Therapeutics INKT -0.92% 31 Total Debt per Share is $0.00 as of Jun. 2026. GuruFocus rates INKT with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

$0.00 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. MiNK Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 was $0.00.

MiNK Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics Total Debt per Share Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial 0.00 0.00 0.00 1.24 1.10

MiNK Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 1.24 1.10 0.00 0.00
INKT
31GF Score
MiNK Therapeutics Inc INKT
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics Total Debt per Share Calculation

MiNK Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+5.18)/4.71
=1.10

MiNK Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.00)/5.10
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.00 mean?
MiNK Therapeutics (INKT) has a Total Debt per Share of $0.00 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on MiNK Therapeutics and its competitors.
Is MiNK Therapeutics' Total Debt per Share too high?
MiNK Therapeutics' current Total Debt per Share is $0.00. Overall, MiNK Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' Total Debt per Share compare to XLO and IMA?
MiNK Therapeutics' Total Debt per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current Total Debt per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current Total Debt per Share of $0.00. The current Total Debt per Share is $0.00. MiNK Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current Total Debt per Share is $0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges 6Q40:Germany
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
31GF Score

Get the complete analysis for INKT

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.32
Price